Skip to main content
Oregon.gov Homepage

Monoclonal antibody therapy (mAb)

Provider Operations ManualManual para ProveedoresTest to Treat LocatorCOVID-19 Therapeutics Locator

Important Updates

  • The process for placing Therapeutics order requests will shift away from Order Request Surveys to directly in HPoP starting 5/12. Ordering through request surveys will continue for the current cycle 5/5/2022 - 5/11/2022, through 5/11; 11:59 PM. Transition cut over date is Thursday 5/12. Request surveys will be turned off and HPoP Direct Ordering will be turned on. If you have not placed orders before and need to be on-boarded to the ordering process please refer to the Provider Operations Manual (Section 1, page 4). 
    • Please review the HPoP supplements in order of priority. These can aslo be found on this page under the "Healthcare Provider Resources" section. 
  • OHA remains committed to equitable distribution of therapeutics. All providers are now eligible to order all theraepeutics. However, due to supply fluctuations, OHA may not be able to fulfill 100% of the courses requested. 

Tixagevimab/Cilgavimab (Evusheld)
  • ​Preexposure prevention of COVID-19
  • Given into the muscle
  • For people not currently infected, no recent exposure, and
    • Moderate to severe immunocompromise, or
    • Can't get vaccinated for medical reasons (severe allergy)

​​Bebtelovimab​

  • Treatment of mild-to-moderate COVID-19 illness
  • Given by vein, within 7 days of symptom onset
  • For people with a positive test, at high risk for severe COVID-19 and no access to other FDA-authorized treatments

All providers are now eligible to order both Euvhseld and Bebtelovimab. OHA remains committed to equitable distribution of all therapeutics, however, due to supply fluctuations, OHA may not be able to fulfill 100% of the courses requested. ​​​


​​​New Providers


Established Providers

  • Submit order requests directly in HPOP
  • Surveys are due on Wednesdays by 11:59 pm to be considered for the current weekly allocation. Surveys submitted after the due date will be considered for the next allocation cycle. 

Weekly federal allocations and provider requests Due to limitations in supply, Oregon Health Authority (OHA) is working to equitably distribute our federal allocation, which is updated weekly.

Sites receiving mAb therapySites listed below are those receiving shipments of mAb therapies in the most recent week. Sites may redistribute their allocation to other providers. This list is not indicative of how much product a location may have available at any given time. If you are seeking mAb therapy for yourself, please contact your provider.


Notes:

Allocations are prioritized to ordering sites weekly, based on the following considerations:

  • Federally Qualified Health Centers & Tribal Health Clinics, which serve communities disproportionately impacted by COVID-19
  • County-level COVID-19 hospitalizations & cases 
  • Sites located in communities disproportionately impacted by COVID-19 (utilizing COVID-19 Community Vulnerability Index)
  • Site-level weekly utilization rate

Download the list



 Contact Us

OHA.therapeutics@dhsoha.state.or.us

 Healthcare Provider Resources

OHA Resources

Webinars for Providers

August 19, 2021 - OHA COVID-19 Senior Health Advisors Dawn Maunter, MD, MS and Shimi Sharief, MD, MPH

Watch the webinarDownload the slides

March 10, 2022 - OHA Outreach Coordinator Greg Desrosiers and Provider Panelists

Watch the webinarDownload the slides

HHS Resources

 Patient Resources

 Visit our treatments page